Clinical Trial Update: Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis [NA]

View source ↗

Summary

A study investigating dupilumab in combination with house dust mite immunotherapy for atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• House Dust Mite Immunotherapy (house dust mite allergen extract)

Snippet

Sponsor: Medical University of Silesia | Conditions: Atopic Dermatitis | NA | Status: COMPLETED